Ocugen pays $15M to Bharat Biotech to extend Covaxin rights in Canada

Date: 2021-06-09   Author: Pankaj Singh  Category: #news

Ocugen pays $15M to Bharat Biotech to extend Covaxin rights in Canada

Ocugen Inc, a biopharmaceutical company, has reportedly announced an upfront payment of $15 million to Bharat Biotech. This transaction is regarding the extension of the rights of Covaxin, a COVID-19 vaccine, to Canada.

In addition, the biopharmaceutical company has reportedly agreed to pay another $10 million to the Indian biotechnology company within 1 month from the commercial launch of the vaccine in the North American country.

Bharat Biotech has recently decided to expand a deal with Ocugen to commercialize the jab in Canada. For the record, the two companies have inked a definitive agreement to co-develop, commercialize, and supply Covaxin in the U.S. market. The biopharmaceutical company further cited that the Amendment is effective as of 29th May 2021. Considering the expansion and pursuant to this Amendment, the company paid a non-refundable, upfront payment worth $15 million to the Indian company and also agreed to pay a milestone payment of $10 million within a month from the 1st commercial sale of the vaccine in Canada.

As per the statement made by Ocugen’s Co-founder, Shankar Musunuri, the company is apparently targeting to gain the EUA (emergency use authorization) of the vaccine in the U.S. as well as seek authorization under interim order for its emergency use in Canada. According to the profit-sharing agreement, it will retain 45% of the profit from the vaccine sales in Canada.

Meanwhile, Bharat Biotech’s Joint MD, Suchitra Ella, has reportedly cited that the company has gained the regulatory approvals for the use of Covaxin in nearly 60 countries including Hungary, Brazil, and the U.S., while the EUA has been obtained in 13 nations. The statement further added that the application for EUL (emergency use listing) has been submitted to the WHO-Geneva. The regulatory approvals are also likely to be received between July to September 2021.

Source credit:

https://www.businesstoday.in/sectors/pharma/ocugen-pays-15-million-to-bharat-biotech-for-covaxin-rights-in-canada/story/441126.html



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Flexible Dies Market 2022, Global Industry Size, Share, Analysis, Trends, Overview and Segmentation 2028

Author: Ashwin Naphade

The Global Flexible Dies Market Report includes a comprehensive analysis of the present industry status offering basic Flexible Dies overview and then goes into each and every detail.

.

Request a sample Report of Flexib...


Overhead Catenary Working Vehicles Market Size, Share, Statistics, Trends, Types, Applications, Analysis and Forecast, Global Industry Research 2028

Author: Ashwin Naphade

Global Overhead Catenary Working Vehicles Market analysis report speaks about the manufacturing process. Global Overhead Catenary Working Vehicles market report analyses the market growth, trends, overview & forecast to 2028.The report covers ...


Global Diesel Multiple Unit (DMU) Market Size, Share, Growth Survey 2022 to 2028 and Industry Analysis Report

Author: Ashwin Naphade

The Global Diesel Multiple Unit (DMU) Market 2022-2028 Renders deep perception of the Market Segment by Regions, market status of the Diesel Multiple Unit (DMU) on a global level that primarily aims the core regions which comprises of continents l...